NCT03186118Active, not recruitingPhase 1
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 12 Jun 2017
- Start date
- 4 Aug 2017
- Primary completion date
- 13 Sept 2021
- Lead sponsor
- Seattle Children's Hospital
- NCT number
- NCT03186118
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 4 Aug 2017 to the primary completion date, 13 Sept 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to enrollment
Other illness
- Evidence of active malignancy other than CD19+ malignancy
Other
- Evidence of active clinically significant CNS dysfunction
Who the study is looking for
- Diagnosis of recurrent or refractory CD19+ leukemia
- Adequate performance status
- Able to tolerate apheresis, including placement of temporary apheresis line if required
- Adequate renal, liver, cardiac, and respiratory function
- Adequate absolute lymphocyte count
- HIV negative; Hepatitis B and C negative within 3 months prior to enrollment.
Age in the registry: 1 year to 30 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seattle Children's Hospital Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.